RET and non-small cell lung carcinoma: Other, recurrent and therapeutically targetable fusion genes involving ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) [16, 17], ret proto-oncogene (RET) [18, 19], B-Raf proto-oncogene, serine/threonine kinase (BRAF) [20], fibroblast growth factor receptor 1–3 (FGFR1-3) [21, 22], neurotrophic receptor tyrosine kinase 1–3 (NTRK1-3) [23], EGFR [24, 25] and MET proto-oncogene, receptor tyrosine kinase (MET) [26, 27] have also been identified in NSCLC patients.